Trial Profile
A Phase 3 Study to Assess the Long Term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 in Subjects With Schizophrenia, Schizophreniform Disorder, or Bipolar I Disorder
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 15 Feb 2024
Price :
$35
*
At a glance
- Drugs Olanzapine/samidorphan (Primary)
- Indications Bipolar I disorders; Psychotic disorders; Schizophrenia
- Focus Adverse reactions; Registrational
- Sponsors Alkermes plc
- 08 Feb 2024 Status changed from active, no longer recruiting to completed.
- 23 Sep 2023 This trial has been completed in Spain and Bulgaria, according to European Clinical Trials Database record.
- 13 Sep 2023 Planned End Date changed from 1 Dec 2023 to 1 Sep 2023.